Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation

Cognitive Impairment Clinical Trial

Official title:

Improving Cognition in People With Progressive Multiple Sclerosis: A Multi-Arm, Randomized, Blinded, Sham-Controlled Trial of Cognitive Rehabilitation and Aerobic Exercise.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03679468
• Other study ID #: 232-2018
• Status: Completed
• Phase: N/A
• Start date: March 18, 2019
• Est. completion date: February 3, 2023

Study information

• Verified date: November 2023
• Source: Sunnybrook Health Sciences Centre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Given that up to 70% of people with secondary progressive MS are cognitively impaired, the search for effective treatments is considered a priority by people living with the disease. This proposal will address the effectiveness of cognitive rehabilitation (CR) and exercise, either alone, or in combination in this regard. A team of MS researchers has been assembled from the USA, Canada, the United Kingdom, Italy, Denmark, Germany and Belgium for this. A total of 360 people with progressive MS will make up the sample. Brain MRIs will be undertaken in a third of the sample before and after the 12 weeks of treatment to document the functional changes that are expected to occur with symptom improvement.

Description:

Aim: The broad aim of this proposal is to evaluate a multidisciplinary and multi-modal approach to rehabilitation in people with progressive MS. Cognitive rehabilitation and aerobic exercise will be evaluated individually and in combinations to address cognitive dysfunction as the primary outcome variable.

Over 20 years have passed since the introduction of the first disease modifying treatment, interferon beta-1betaseron (b), for multiple sclerosis (MS).Since then 13 treatments have been approved and made it onto the market. All are for relapsing-remitting disease (RRMS), apart from mitoxantrone which is limited to progressive disease with relapses, Interferon-beta-1b, which is for secondary progressive disease (SPMS), but does not delay disability progression and Ocrelizumab for primary progressive MS only. Thus, for a sizeable proportion of people with MS there is no therapeutic option to slow progression. This raises the question, how are patients with primary and secondary progressive MS (PPMS and SPMS) to be helped? While research is underway to find a medication that holds promise of halting further deterioration in a disease that has already entered a progressive stage, patients and their clinicians are left with basically symptomatic treatments.

Hypothesis: The investigators hypothesize that CR and aerobic exercise are effective treatments for cognitive impairment (processing speed deficits) in people with progressive MS. In particular a combination of these two treatment given twice weekly over 12 weeks is more effective than each individual treatment given alone or as sham. The investigators further hypothesize that improvements in processing speed will be matched on functional MRI (fMRI) by enhanced neural activity in networks associated with information processing speed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 309
• Est. completion date: February 3, 2023
• Est. primary completion date: October 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 65 Years

Eligibility

Inclusion Criteria:

• Have a confirmed diagnosis of progressive Multiple Sclerosis

• Visual Acuity of 20/70

• Language comprehension, to ensure subjects have the ability to understand instructions

Exclusion Criteria:

• Wheelchair dependent (EDSS > 7.0)

• History of central nervous system disease other than progressive MS

• Steroids use within the past 3 months

• Regular aerobic training (eg. bi-cycling, running, swimming or rowing)

• Unwilling to travel to study sites for rehabilitation 2 times a week for 3 months

Related Conditions & MeSH terms

• Cognitive Impairment
• Multiple Sclerosis
• Multiple Sclerosis, Chronic Progressive
• Multiple Sclerosis, Primary Progressive
• Sclerosis

Intervention

Other:
• Cognitive Rehabilitation
RehaCom software Information processing speed and attention modules
• Sham Exercise
Sets of balance and stretching exercises
• Sham Cognitive Rehabilitation
Kompozer software 24 session module consisting of basic internet searches
• Aerobic Exercise
Recumbent NuStep Bike Aerobic cycling

Locations

Country	Name	City	State
Canada	Sunnybrook Health Science Center	Toronto	Ontario

Sponsors (12)

Lead Sponsor	Collaborator
Sunnybrook Health Sciences Centre	Fondazione Italiana Sclerosi Multipla, Hasselt University, Kessler Foundation, Ospedale San Raffaele, Unity Health Toronto, Universita degli Studi di Genova, University College, London, University of Alabama at Birmingham, University of Florence, University of Plymouth, University of Southern Denmark

Country where clinical trial is conducted

Canada, 

References & Publications (10)

Chiaravalloti ND, Amato MP, Brichetto G, Chataway J, Dalgas U, DeLuca J, Meza C, Moore NB, Feys P, Filippi M, Freeman J, Inglese M, Motl R, Rocca MA, Sandroff BM, Salter A, Cutter G, Feinstein A; CogEx Research Team. The emotional impact of the COVID-19 p — View Citation

Feinstein A, Amato MP, Brichetto G, Chataway J, Chiaravalloti N, Dalgas U, DeLuca J, Feys P, Filippi M, Freeman J, Meza C, Inglese M, Motl RW, Rocca MA, Sandroff BM, Salter A, Cutter G; CogEx Research Team. Study protocol: improving cognition in people wi — View Citation

Feinstein A, Amato MP, Brichetto G, Chataway J, Chiaravalloti ND, Cutter G, Dalgas U, DeLuca J, Farrell R, Feys P, Filippi M, Freeman J, Inglese M, Meza C, Motl R, Rocca MA, Sandroff BM, Salter A; CogEx Research Team. The impact of the COVID-19 pandemic o — View Citation

Feinstein A, Amato MP, Brichetto G, Chataway J, Chiaravalloti ND, Cutter G, Dalgas U, DeLuca J, Farrell R, Feys P, Filippi M, Freeman J, Inglese M, Meza C, Motl RW, Rocca MA, Sandroff BM, Salter A; CogEx Research Team. Cognitive rehabilitation and aerobic — View Citation

Feinstein A, Amato MP, Brichetto G, Chataway J, Chiaravalloti ND, Cutter G, Dalgas U, DeLuca J, Farrell R, Feys P, Filippi M, Freeman J, Inglese M, Meza C, Motl RW, Rocca MA, Sandroff BM, Salter A; CogEx Research Team. The late onset of emotional distress — View Citation

Feinstein A. The CogEx trial - Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis: A randomised, blinded, sham-controlled trial. Mult Scler. 2023 Nov 2:13524585231210178. doi: 10.1177/13524 — View Citation

Preziosa P, Rocca MA, Pagani E, Valsasina P, Amato MP, Brichetto G, Bruschi N, Chataway J, Chiaravalloti ND, Cutter G, Dalgas U, DeLuca J, Farrell R, Feys P, Freeman J, Inglese M, Meani A, Meza C, Motl RW, Salter A, Sandroff BM, Feinstein A, Filippi M; th — View Citation

Romano F, Motl RW, Valsasina P, Amato MP, Brichetto G, Bruschi N, Chataway J, Chiaravalloti ND, Cutter G, Dalgas U, DeLuca J, Farrell R, Feys P, Freeman J, Inglese M, Meza C, Salter A, Sandroff BM, Feinstein A, Rocca MA, Filippi M; CogEx Research Team. Ab — View Citation

Sandroff BM, Motl RW, Amato MP, Brichetto G, Chataway J, Chiaravalloti ND, Cutter GR, Dalgas U, DeLuca J, Farrell R, Feys P, Filippi M, Freeman J, Inglese M, Meza C, Rocca MA, Salter A, Feinstein A. Cardiorespiratory fitness and free-living physical activ — View Citation

Veldkamp R, D'hooge M, Sandroff BM, DeLuca J, Kos D, Salter A, Feinstein A, Amato MP, Brichetto G, Chataway J, Farrell R, Chiaravalloti ND, Dalgas U, Filippi M, Freeman J, Motl RW, Meza C, Inglese M, Rocca MA, Cutter G, Feys P; CogEx Research Team. Profil — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change from baseline brain activity at 12 weeks and 6 months	The participant will perform a modified Go no Go task while in the MRI. Changes in brain activity will indicate superiority of one of the four study groups.; Go no Go task: Participants are required to either respond (i.e., pressing designated key) or withhold a response (not pressing designated key) depending on whether a go stimulus or a no-go stimulus is presented; MRI Go no Go task will be administered at index assessment, 12 weeks following cognitive rehab/ aerobic exercise, and at 6 months to examine brain activity and anatomical changes	Baseline, 12 weeks, 6 months
Primary	Change from baseline cognitive Information processing speed at 12 weeks and 6 months	The Symbol Digit Modalities Test (SDMT) will be used to measure cognitive information processing speed; The SDMT is a simple matching task that requires the participant to refer to a reference key, in order to correctly match a geometric symbol with the corresponding number. Participant will be under a 90 second time constraint to quickly and correctly match each pair.; Test will be administered at index assessment, 12 weeks following cognitive rehab/ aerobic exercise, and at 6 months to examine cognitive retention	Baseline, 12 weeks, and 6 month
Secondary	Change from baseline cognitive verbal memory at 12 weeks and 6 months	The California Verbal Learning Test (CVLT) will be used to measure verbal memory; The CVLT test begins with the examiner reading a list of 16 words, participants are then instructed to report as many of the words as they can remember. After recall is recorded, the entire list is read again, altogether, there are five learning trials.; Test will be administered at index assessment, 12 weeks following cognitive rehab/ aerobic exercise, and at 6 months to examine cognitive retention	Baseline, 12 weeks, & 6 month
Secondary	Change from baseline cognitive visual memory at 12 weeks and 6 months	The Brief Visuo-Spatial Memory Test (BVMT) will be used to measure visual memory; Participants are presented with six abstract designs for 10 seconds, the display is then removed from view and participant are instructed to draw the designs from memory via pencil on paper. Each design is scored from 0 to 2 points representing accuracy and location. There are three learning trials.; Test will be administered at index assessment, 12 weeks following cognitive rehab/ aerobic exercise, and at 6 months to examine cognitive retention	Baseline, 12 weeks, & 6 month
Secondary	Change from baseline anxiety & depression, at 12 weeks and 6 months	The following self report scale will be used to measure anxiety and depression: The Hospital Anxiety and Depression Scale (HADS) - The HADS is comprised of seven questions for anxiety and seven questions for depression, each reply has a likert scale ranging from 0-3.; Total score will indicate: 0-7 = normal 8-10 = borderline abnormal 11-21 = abnormal	Baseline, 12 weeks, and 6 month
Secondary	Change from baseline depression, at 12 weeks and 6 months	The following self report scale will be used to measure depression: Beck Depression Inventory-revised (BDI-II) - The BDI-II questionnaire is comprised of 21 questions, participant will circle a reply that closely matches their answer, each reply has a likert scale that ranges from 0-3.; Total score indicate the following: 1-10 = these ups and downs are considered normal 11-16 = Mild mood disturbance 17-20 = Borderline clinical depression 21-30 = Moderate depression 31-40 = Severe depression over 40 = Extreme depression	Baseline, 12 weeks, and 6 month
Secondary	Change from baseline fatigue, at 12 weeks and 6 months	Self report scale: The Modified Fatigue Impact Scale (MFIS), will evaluate the participants fatigue.; The total score for the MFIS is the sum of the scores for the 21 items. Individual subscale scores for physical, cognitive, and psychosocial functioning can also be generated by calculating the sum of specific sets of items.	Baseline, 12 weeks, and 6 month
Secondary	Change from baseline perceived deficits, at 12 weeks and 6 months	Self report scale: The Perceived Deficits Questionnaire (PDQ), will evaluate the participants subjective cognitive difficulties.; The total score for the PDQ is the sum of the scores for the 20 items. Individual subscale scores for attention/concentration, retrospective memory, prospective memory, and planning/organization will be generated by calculating the sum of specific sets of items.	Baseline, 12 weeks, and 6 month
Secondary	Change from baseline subjective impact of walking, at 12 weeks and 6 months	Self report scale: The Multiple Sclerosis Walking Scale (MSWS-12), will evaluate the participants subjective impact of walking.; The MSWS-12 consist of 12 questions, each question ranges from 0-5. A high total score indicates greater impact on walking than lower scores.	Baseline, 12 weeks, and 6 month
Secondary	Change from baseline impact of Multiple Sclerosis, at 12 weeks and 6 months	Self report scale: Multiple Sclerosis Impact Scale (MSIS-29-V2) - will evaluate the participants impact of Multiple Sclerosis.; The MSIS-29 is a 29 item scale measuring the physical (20 item) and psychological (9 item) impact of Multiple scleroses.	Baseline, 12 weeks, and 6 month
Secondary	Change from baseline quality of life, at 12 weeks and 6 months	Self report scale: European Quality of Life-5 Dimensions (EQ5D-5) - will be used to evaluate the participants quality of life.; The EQ5D-5 comprises of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.; The EQ5D-5 also records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled "The best health you can imagine" and "The worst health you can imagine".	Baseline, 12 weeks, and 6 month
Secondary	Change from baseline global function, at 12 weeks and 6 months	Self report scale: The Functional Assessment of Multiple Sclerosis (FAMS), will be used to asses the participants global function.; The FAMS consist of 59 items, and domains that consist of questions on: mobility, symptoms, emotional well-being, general contentment, thinking/fatigue, family/social well-being, and additional concerns.; FAMS total score range = 0 -176. Higher scores indicate better quality of life.	Baseline, 12 weeks, and 6 month